Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation

Heart Lung and Circulation

Volumn 26, Issue 9, 2017, Pages 934-940

  Lau, Dennis H ^a   Thiyagarajah, Anand ^a   Willems, Stephan ^b   Rostock, Thomas ^c   Linz, Dominik ^a   Stiles, Martin K ^d   Kaye, David ^e   Kalman, Jonathan M ^f   Sanders, Prashanthan ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY HEART CENTER HAMBURG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d WAIKATO HOSPITAL   (New Zealand)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Atrial fibrillation; Atrioventricular nodal ablation; Cardiac resynchronisation therapy; Device therapy

Indexed keywords

ABLATION THERAPY; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE ABLATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; DEVICE THERAPY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PACING; HEART VENTRICLE CONTRACTION; HUMAN; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RIGHT VENTRICULAR PACING; SYSTOLIC HEART FAILURE; TACHYCARDIA; CATHETER ABLATION; HEART ATRIOVENTRICULAR NODE; HEART RATE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SURGERY;

ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; CARDIAC PACING, ARTIFICIAL; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; HEART RATE; HUMANS;

EID: 85021770987     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2017.05.124     Document Type: Review

References (54)

1. Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:12 (2007), 857–867.
2. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 323:22 (1990), 1505–1511.
3. Van Gelder, C., Hagens, V.E., Bosker, H.A., Kingma, J.H., Kamp, O., Kingma, T., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:23 (2002), 1834–1840.
4. Wyse, D.G., Waldo, A.L., DiMarco, J.P., Domanski, M.J., Rosenberg, Y., Schron, E.B., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:23 (2002), 1825–1833.
5. Roy, D., Talajic, M., Nattel, S., Wyse, D.G., Dorian, P., Lee, K.L., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:25 (2008), 2667–2677.
6. Hohnloser, S.H., Kuck, K.H., Lilienthal, J., Rhythm or rate control in atrial fibrillation–Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356:9244 (2000), 1789–1794.
7. Carlsson, J., Miketic, S., Windeler, J., Cuneo, A., Haun, S., Micus, S., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41:10 (2003), 1690–1696.
8. Kotecha, D., Piccini, J.P., Atrial fibrillation in heart failure: what should we do?. Eur Heart J 36:46 (2015), 3250–3257.
9. Passos, L.C., Oliveira, M.G., Duraes, A.R., Trindade, T.M., Barbosa, A.C., Initiation or maintenance of beta-blocker therapy in patients hospitalized for acute heart failure. Int J Clin Pharm 38:4 (2016), 802–807.
10. Van Gelder, I.C., Groenveld, H.F., Crijns, H.J., Tuininga, Y.S., Tijssen, J.G., Alings, A.M., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:15 (2010), 1363–1373.
11. Dong, K., Shen, W.K., Powell, B.D., Dong, Y.X., Rea, R.F., Friedman, P.A., et al. Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. Heart Rhythm 7:9 (2010), 1240–1245.
12. Gasparini, M., Auricchio, A., Metra, M., Regoli, F., Fantoni, C., Lamp, B., et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 29:13 (2008), 1644–1652.
13. Ganesan, A.N., Brooks, A.G., Roberts-Thomson, K.C., Lau, D.H., Kalman, J.M., Sanders, P., Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol 59:8 (2012), 719–726.
14. Fenelon, G., Wijns, W., Andries, E., Brugada, P., Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 19:1 (1996), 95–106.
15. Cruz, F.E., Cheriex, E.C., Smeets, J.L., Atie, J., Peres, A.K., Penn, O.C., et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol 16:3 (1990), 739–744.
16. Gopinathannair, R., Etheridge, S.P., Marchlinski, F.E., Spinale, F.G., Lakkireddy, D., Olshansky, B., Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol 66:15 (2015), 1714–1728.
17. Calo, L., De Ruvo, E., Sette, A., Sciarra, L., Scioli, R., Sebastiani, F., et al. Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med (Hagerstown) 8:3 (2007), 138–143.
18. Redfield, M.M., Kay, G.N., Jenkins, L.S., Mianulli, M., Jensen, D.N., Ellenbogen, K.A., Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 75:8 (2000), 790–795.
19. Deedwania, P.C., Lardizabal, J.A., Atrial fibrillation in heart failure: a comprehensive review. Am J Med 123:3 (2010), 198–204.
20. Sanders, P., Morton, J.B., Davidson, N.C., Spence, S.J., Vohra, J.K., Sparks, P.B., et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 108:12 (2003), 1461–1468.
21. Lau, D.H., Psaltis, P.J., Mackenzie, L., Kelly, D.J., Carbone, A., Worthington, M., et al. Atrial remodeling in an ovine model of anthracycline-induced nonischemic cardiomyopathy: remodeling of the same sort. J Cardiovasc Electrophysiol 22:2 (2011), 175–182.
22. Wang, T.J., Larson, M.G., Levy, D., Vasan, R.S., Leip, E.P., Wolf, P.A., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:23 (2003), 2920–2925.
23. Chiang, C.E., Naditch-Brule, L., Murin, J., Goethals, M., Inoue, H., O'Neill, J., et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 5:4 (2012), 632–639.
24. Maisel, W.H., Stevenson, L.W., Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91:6a (2003), 2d–8d.
25. Boldt, L.H., Rolf, S., Huemer, M., Parwani, A.S., Luft, F.C., Dietz, R., et al. Optimal heart failure therapy and successful cardioversion in heart failure patients with atrial fibrillation. Am Heart J 155:5 (2008), 890–895.
26. Scheinman, M.M., Huang, S., The 1998 NASPE prospective catheter ablation registry. PACE – Pacing and Clinical Electrophysiology 23:6 (2000), 1020–1028.
27. Feld, G.K., Radiofrequency catheter ablation versus modification of the AV node for control of rapid ventricular response in atrial fibrillation. J Cardiovasc Electrophysiol 6:3 (1995), 217–228.
28. Vlachos, K., Letsas, K.P., Korantzopoulos, P., Liu, T., Efremidis, M., Sideris, A., et al. A review on atrioventricular junction ablation and pacing for heart rate control of atrial fibrillation. J Geriatr Cardiol 12:5 (2015), 547–554.
29. January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C. Jr., et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:23 (2014), e199–e267.
30. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:38 (2016), 2893–2962.
31. Ellis, E.R., Josephson, M.E., What About Tachycardia-induced Cardiomyopathy?. Arrhythm Electrophysiol Rev 2:2 (2013), 82–90.
32. Kay, G.N., Ellenbogen, K.A., Giudici, M., Redfield, M.M., Jenkins, L.S., Mianulli, M., et al. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol 2:2 (1998), 121–135.
33. Ozcan, C., Jahangir, A., Friedman, P.A., Munger, T.M., Packer, D.L., Hodge, D.O., et al. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. Am J Cardiol 92:1 (2003), 33–37.
34. Manolis, A.G., Katsivas, A.G., Lazaris, E.E., Vassilopoulos, C.V., Louvros, N.E., Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol 2:1 (1998), 71–76.
35. Twidale, N., McDonald, T., Nave, K., Seal, A., Comparison of the effects of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation. Pacing Clin Electrophysiol 21:4 Pt 1 (1998), 641–651.
36. Natale, A., Zimerman, L., Tomassoni, G., Newby, K., Leonelli, F., Fanelli, R., et al. AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: effect on quality of life and exercise performance. Pacing Clin Electrophysiol 22:11 (1999), 1634–1639.
37. Herbert, W.H., Cardiac output and the varying R-R interval of atrial fibrillation. J Electrocardiol 6:2 (1973), 131–135.
38. Morris, J.J. Jr., Entman, M., North, W.C., Kong, Y., McIntosh, H., The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm. Circulation 31 (1965), 670–678.
39. Clark, D.M., Plumb, V.J., Epstein, A.E., Kay, G.N., Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 30:4 (1997), 1039–1045.
40. Marshall, H.J., Harris, Z.I., Griffith, M.J., Holder, R.L., Gammage, M.D., et al. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. Circulation 99:12 (1999), 1587–1592.
41. Brignole, M., Menozzi, C., Gianfranchi, L., Musso, G., Mureddu, R., Bottoni, N., et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 98:10 (1998), 953–960.
42. Brignole, M., Gianfranchi, L., Menozzi, C., Alboni, P., Musso, G., Bongiorni, M.G., et al. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 96:8 (1997), 2617–2624.
43. Ueng, K.C., Tsai, T.P., Tsai, C.F., Wu, D.J., Lin, C.S., Lee, S.H., et al. Acute and long-term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol 12:3 (2001), 303–309.
44. Chatterjee, N.A., Upadhyay, G.A., Ellenbogen, K.A., McAlister, F.A., Choudhry, N.K., Singh, J.P., Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol 5:1 (2012), 68–76.
45. Sharma, A.D., Rizo-Patron, C., Hallstrom, A.P., O'Neill, G.P., Rothbart, S., Martins, J.B., et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm 2:8 (2005), 830–834.
46. Steinberg, J.S., Fischer, A., Wang, P., Schuger, C., Daubert, J., McNitt, S., et al. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J Cardiovasc Electrophysiol 16:4 (2005), 359–365.
47. Bristow, M.R., Saxon, L.A., Boehmer, J., Krueger, S., Kass, D.A., De Marco, T., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:21 (2004), 2140–2150.
48. Hayes, D.L., Boehmer, J.P., Day, J.D., Gilliam, F.R. 3rd, Heidenreich, P.A., Seth, M., et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 8:9 (2011), 1469–1475.
49. Kamath, G.S., Cotiga, D., Koneru, J.N., Arshad, A., Pierce, W., Aziz, E.F., et al. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. J Am Coll Cardiol 53:12 (2009), 1050–1055.
50. Upadhyay, G.A., Steinberg, J.S., Managing atrial fibrillation in the CRT patient: controversy or consensus?. Heart Rhythm 9:8 Suppl (2012), S51–S59.
51. Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF). Retrieved from http://www.clinicaltrials.gov/ct2/show/NCT01522898. Last Accessed 1st May 2017.
52. Doshi, R.N., Daoud, E.G., Fellows, C., Turk, K., Duran, A., Hamdan, M.H., et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 16:11 (2005), 1160–1165.
53. Brignole, M., Botto, G., Mont, L., Iacopino, S., De Marchi, G., Oddone, D., et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 32:19 (2011), 2420–2429.
54. Khan, M.N., Jais, P., Cummings, J., Di Biase, L., Sanders, P., Martin, D.O., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359:17 (2008), 1778–1785.